Retinitis pigmentosa: the night vision that goes first, the inheritance questions, and the life built around the sight that stays
Last updated September 3, 2026.
Retinitis pigmentosa, RP, is a group of inherited conditions in which the light-sensing cells of the retina slowly die, and it announces in a characteristic order: night vision goes first, the rod cells fail before the cone cells, then the edges of vision narrow toward the center over years, the tunnel vision, while the central reading vision often holds for a long time. It is one of the commonest inherited causes of visual impairment, usually beginning in youth or early adulthood, and its pace varies widely between families and between the genes that cause it. The diagnosis comes from the eye examination, the electroretinogram that measures the retina's electrical response, the visual field test, and increasingly the genetic test, which matters more than it used to: knowing the exact gene is now the gateway to the new treatments. The treatment landscape has changed: one gene therapy exists for a specific RP gene, more gene-directed treatments are in trials, and the practical supports, low-vision services, orientation and mobility training, and the technology that reads the world aloud, let people build full lives around the sight that stays. The worth-knowing parts: vitamin A supplementation is sometimes discussed and only ever taken under the specialist's direction; protecting the eyes from excess light is sensible; the driving question should be faced early and honestly, because night driving goes first; and the low-vision clinic and the charities are where the practical life gets rebuilt, not the hospital.
What does it look like?
Night blindness first: struggling in cinemas, restaurants, and dusk, tripping over things in low light, while daytime vision still seems fine. Then the edges: bumping into people and door frames, losing the ball in sports, the visual field narrowing over years toward the center. Central reading vision often holds into middle life or beyond. Some forms add cataracts early, and some affect hearing too, which is why the team asks.
Why does it happen?
RP is genetic: one of dozens of possible gene changes disrupts the retina's light-sensing cells, and the inheritance pattern varies, some forms pass from an affected parent, some need a gene copy from each parent, some track the X chromosome, and many cases arrive with no family history at all. The genetic test sorts which gene and which pattern, which answers the family questions and increasingly opens the door to gene-specific trials and treatments.
How is it treated?
- The genetic test is the gateway. Knowing the exact gene answers the inheritance questions and opens the gene-specific treatments and trials, including the one approved gene therapy for a specific RP gene.
- Low-vision services rebuild the practical life. Lighting, contrast, magnification, screen-reading technology, and orientation and mobility training: this is where independence is kept, and referral is a milestone, not a defeat.
- The complications get treated. Cataracts can be removed, the retinal swelling that sometimes comes gets treated, and regular monitoring catches both.
- The future-facing choices get support. The driving conversation, the family-planning conversation with genetic counseling, and the vitamin A question, only under specialist direction, all have proper homes in the care pathway.
When does it need prompt review?
A sudden drop or distortion in vision, rather than the usual slow change, earns a prompt appointment, because the treatable complications, retinal swelling above all, announce that way. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
There is no cure. What is my actual future?
The no-cure sentence is true and incomplete, and the completion matters. What RP does: it takes night vision and the edges of vision slowly, over years to decades, while the central reading-and-screen vision typically holds longest, often into middle life and beyond, and the pace varies widely between people and genes. What is changing: the treatment landscape has moved more in the last ten years than in the previous fifty. One gene therapy exists for a specific RP gene, and the pipeline of gene-directed treatments is fuller for this group of conditions than for almost any other inherited disease. Nobody honest gives you a cure on a date, but at 22 the treatments arriving this decade are arriving for you, and the genetic test is what makes you findable by them. And the life built around the sight that stays is not a consolation: the technology, the training, and the careers, engineering among them, are real and well mapped.
What does the genetic test actually do for me?
It turns a label into a key. RP is not one disease but dozens, each caused by a different gene, and the test sorts which one you carry. That answer does three concrete things: it tells your family which inheritance pattern applies, who should be tested, and what the risks are for your future children; it tells your specialists which complications and which pace to expect, because the genes differ; and it determines which gene-specific treatments and trials you are eligible for, including the one approved gene therapy, which works only for one specific gene. Trials increasingly recruit by genotype, not by diagnosis, so the result is how the future treatments find you. Ask the clinic for a copy of your result and keep it with your records, because you will need it for every trial conversation.
Should I get on clinical trials, and how do I find them?
Registering interest is worth doing early, because the trials are where this field is moving and eligibility is gene-specific, age-specific, and sometimes stage-specific. The practical route: get the genetic result first, because most trials screen on it; ask your specialist center which trials and registries they are linked to, because the major eye hospitals run or know them; and register with the national inherited-retinal-disease registries and the charity trial-finders, which match patients to studies. The honest guidance on participation: trials are research, not treatment, some involve placebo arms, and the eligibility criteria are strict, but even an unsuccessful application puts you on the lists the field uses. Your specialist team should be your first conversation, because they can flag anything recruiting that fits your gene and your stage.
I have not told my parents. My mum will blame herself. What do I say?
Tell them with the plan attached, and give your mother the fact that lifts the blame in the first minute: no parent causes or could have prevented this, many cases arrive with no family history at all, like yours, and the genetic result will explain the inheritance for the whole family, her included. The self-blame is what mothers do with a diagnosis; the corrective is information, and the information is on your side. The plan attached is the other half: you are 22, tested, monitored, trial-aware, and finishing a degree in a field this condition accommodates. Parents absorb frightening news far better when it arrives with its own structure, and the conversation, hard as it is, ends the loneliest part of this, the carrying it alone. The charities that support RP families talk to parents as routinely as to patients, and your mother may want their number as much as you do.
Can I still drive, and what about night driving?
Night driving goes first, and facing that early is the honest version of coping: the night blindness that took you out of cinemas applies to unlit roads, and most people with RP make the call themselves, restricting to daylight and familiar routes before the license question becomes official. The legal position depends on your visual field and acuity against the licensing standard, which your clinic measures and knows; the field test you will have at intervals is the same measurement the licensing authority cares about. The longer arc is worth saying plainly too: many people with RP do stop driving at some point, and the people who cope best are the ones who build the alternatives, the location choices, the transport habits, the mobility training, before they need them rather than after. It is a loss, and it is a manageable one, and the managing starts early.
Will my children have this?
It depends entirely on which gene and which inheritance pattern your result shows, and that answer is coming, which is one of the practical reasons the blood test matters. The three patterns work differently: if your form is recessive, your children would need a matching gene from the other parent, which is rare unless there is relatedness in the family; if it is dominant, each child has a one-in-two chance; if it tracks the X chromosome, the risks differ for sons and daughters. Many cases with no family history, like yours, turn out to be recessive or brand-new mutations, both of which carry lower risks for your children than people fear. The genetic counseling that follows your result is the place for this conversation, and it covers not just the risks but the options, because modern reproductive medicine has answers for couples who want them. You do not have to have this conversation with a future partner armed with guesses; you will have it armed with the result.